©2024 Stanford Medicine
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Not Recruiting
Trial ID: NCT00186433
Purpose
1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA
concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients
with nasopharyngeal carcinoma (NPC).
2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these
tumors both in endemic and non-endemic areas.
3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for
both endemic and non-endemic patient populations.
Official Title
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Stanford Investigator(s)
Quynh-Thu Le, MD
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
James L. Zehnder, M.D.
Professor of Pathology (Research) and of Medicine (Hematology)
Harlan Pinto
Associate Professor of Medicine (Oncology) and of Otolaryngology - Head & Neck Surgery
Billy W Loo, Jr, MD PhD FASTRO FACR
Professor of Radiation Oncology (Radiation Therapy)
Eligibility
Inclusion Criteria:
- Having a new diagnosis of Nasopharyngeal carcinoma.
- Being treated with either radiotherapy or chemoradiotherapy for this condition.
Exclusion Criteria:
- Age <18 since NPC is a very rare condition in this age group and may have a different
biological behavior
- Patients who are unable to provide informed consents for themselves.
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Quynh-Thu Le
650-498-6184